La Jolla Pharmaceutical (LJPC) 10-Q2018 Q1 Quarterly report

Filed: 10 May 18, 4:39pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abstract, accrual, adhered, adjust, adjusted, adjusting, AKI, allocate, analyzed, APACHE, arm, ASC, bruising, building, card, center, chapter, chargeback, chelation, Codification, collateral, Conference, connection, content, cost, credit, CRRT, daily, delivery, demand, deposit, depreciation, disruption, distributor, equivalent, exceeding, fatigue, ferritin, FIFO, frequency, GIAPREZA, GIAPREZATM, group, HCR, healthcare, high, holder, hour, iii, imaging, inability, injection, injury, inventory, key, labeling, launch, lieu, LLC, lower, lt, magnetic, manner, manufacture, manuscript, maximum, medical, met, mg, mL, MRI, multinational, Nephrology, newly, obligation, obsolete, online, pay, people, Pharma, phlebotomy, Physiology, pint, pledged, poor, procedure, producing, promotional, prompt, puncture, realizable, recourse, red, regimen, removal, renal, replacement, resonance, return, royalty, RRT, saturation, scarring, SCCM, score, security, selling, septic, service, shipment, shipping, standby, sterile, stored, subsidiary, successfully, threshold, tiered, tissue, transferrin, typically, ultimately, variable, vary, vasoconstrictor, week, weekly, wholly, worldwide

Removed: active, amendment, antimicrobial, approach, Assessment, assumption, biologic, broad, called, canceled, caption, cardiovascular, catecholamine, chemical, clinically, closely, collaboration, commencement, commencing, comparative, comparison, comprehensive, consistent, controlled, dangerously, dated, debt, depend, derivative, determining, differentially, directly, distinct, dividend, driven, DSMB, earliest, employee, equal, existing, expansion, fair, fiscal, forfeiture, function, funding, generate, gentamicin, grant, hypotension, identified, impacted, implement, initiate, lack, marketed, meeting, mixture, model, Monitoring, NDA, negotiated, noted, notice, obtaining, Organ, originally, par, permitted, planned, point, prescribed, pricing, professional, profile, profit, prospectively, protocol, purified, recommended, reduced, reference, reimbursement, relevant, resistant, retain, seek, Sequential, set, simplified, SOFA, SPA, spectrum, supplemented, table, tolerability, toxicity, traditional, unaffiliated, undertaken, volatility, written, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

LJPC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned, in his capacity as an officer of La Jolla Pharmaceutical Company (Registrant), hereby certifies, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


•	the Quarterly Report of the Registrant on Form 10-Q for the quarter ended March 31, 2018 (Report), which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


•	the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter.




Date:	May 10, 2018	/s/ George F. Tidmarsh
		George F. Tidmarsh, M.D., Ph.D.
		President, Chief Executive Officer and Secretary
		(Principal Executive Officer)

		/s/ Dennis M. Mulroy
		Dennis M. Mulroy
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Note: A signed original of this written statement required by Section 906 has been provided to La Jolla Pharmaceutical Company and will be retained by La Jolla Pharmaceutical Company and furnished to the Securities and Exchange Commission or its staff upon request.